Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Regeneron Pharmaceuticals
With
Bayer
Qualified subjects will be randomized to one of 5 treatment arms. The active (treatment) phase of the study will be 52 weeks, with a 6 month safety follow-up
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with clinically significant DME with central involvement
Adults 18 years or older with type 1 or 2 diabetes mellitus with diabetic macular edema
ETDRS BCVA: 20/40 to 20/320 (letter score of 73 to 24) in the study eye
You may not be if
History of vitreoretinal surgery in the study eye
Panretinal laser photocoagulation or macular laser photocoagulation in the study eye within 3 months of screening
Previous use of intraocular or periocular corticosteroids in the study eye within 3 months of screening
Previous treatment with anti-angiogenic drugs in either eye (pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc) within 3 months of screening
Uncontrolled diabetes mellitus
Uncontrolled hypertension defined as systolic \> 180mmHg or \> 160 mmHg on 2 consecutive measurements or diastolic \> 100 mmHg on optimal medical regimen
Ocular disorders in the study eye, other than DME, that may confound interpretation of study results
